Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Non small cell lung cancer future or investigational therapies
Introduction
Overview
Overview
The KEYNOTE-024 trial used pembrolizumab (a monoclonal antibody against programmed death 1) in patients with advanced non-small cell lung cancer and PD-L1 expression. Pembrolizumab was associated with significantly longer progression-free and overall survival. The reported adverse events were lower than those of platinum-based chemotherapy. [1]
Future or Investigational Therapies
Future or Investigational Therapies
KEYNOTE-024 trial
- Phase III, open-label, randomized clinical trial[2]
- Patients with untreated, advanced non-small cell lung cancer and PD-L1 expression[2]
- Pembrolizumab was associated with:[2]
- Significantly longer progression-free (10.3 months) and overall survival at 6 months (80.2%)
- Low adverse events compared to platinum-based chemotherapy
References
References
- ↑ Martin Reck, M.D. et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. October 9 2016 DOI: 10.1056/NEJMoa1606774 http://www.nejm.org/doi/full/10.1056/NEJMoa1606774
- ↑ 2.0 2.1 2.2 Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY; et al. (2016). “Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial”. Lancet. 387 (10027): 1540–50. doi:10.1016/S0140-6736(15)01281-7. PMID 26712084.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]